BiotechTubeBiotechTube
Home/Lexeo Therapeutics/Dr. Jay Barth
DJ

Dr. Jay Barth

Chief Medical Officer

Lexeo Therapeutics

Therapeutic Areas

CardiovascularCentral Nervous SystemRare Diseases

Lexeo Therapeutics Pipeline

DrugIndicationPhase
LX2006Friedreich's ataxia cardiomyopathyPhase 1/2
LX1001APOE4-associated Alzheimer's disease (homozygous)Phase 1/2
LX2020Barth syndrome (TAZ gene mutation)Preclinical
LX2021Danon disease (LAMP2 gene mutation)Preclinical
Unnamed ProgramFriedreich's ataxia (neurological manifestations)Research

Leadership Team at Lexeo Therapeutics

RN
R. Nolan Townsend
Chief Executive Officer
DP
Dr. Paul Hearty
Chief Business Officer
RD
Richard Daly
Chairman of the Board (Former CEO)
DF
Dr. Federico Mingozzi
Chief Scientific Officer
DD
Dr. Douglas Ingram
Board Director
DJ
Dr. Jeffrey Marrazzo
Board Director
DK
Dr. Katherine High
Board Director and Co-founder
DS
Dr. Steven Hyman
Board Director
AM
Anand Mehra
Board Director
DD
Dr. David Lebwohl
Former Chief Medical Officer
View full Lexeo Therapeutics profile